Abstract
The paired box 3 (PAX3), a crucial transcription factor, is normally expressed during embryonic development and is absent in normal adult human tissues. Deregulated expression of PAX3 has been observed in tumors like rhabdomyosarcoma and melanomas. To assess deregulated PAX3 expression in patients with gliomas, these samples from 57 glioma patients (13 grade I, 16 grade II, 14 grade III, and 14 grade IV tumors) and 10 normal brain specimens acquired from 10 patients undergoing surgery for epilepsy as control were obtained. PAX3 expression was measured by RT-PCR, Western blot, and immunohistochemistry. Survival analyses were performed using the Kaplan–Meier method. Association between PAX3 expression, clinicopathological characteristics, and patients’ survival were analyzed by using SPSS 17.0. We found that the expression of PAX3 was upregulated in high-grade glioma tissues compared with that in low-grade and normal brain tissues, and increased with ascending tumor World Health Organization (WHO) grades (P = 0.001). The increased PAX3 expression in gliomas was significantly associated with higher WHO grade (P = 0.021) and poorer disease-specific survival of patients (P = 0.001). Our results suggested that PAX3 might be an intrinsic regulator of progression in glioma cells and it might serve as a prognostic factor for this dismal disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barr FG, Fitzgerald JC, Ginsberg JP, Vanella ML, Davis RJ, Bennicelli JL (1999) Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines. Cancer Res 59:5443–5448
Blake JA, Thomas M, Thompson JA, White R, Ziman M (2008) Perplexing Pax: from puzzle to paradigm. Dev Dyn 237:2791–2803
Brandes AA (2003) State-of-the-art treatment of high-grade brain tumors. Semin Oncol 30:4–9
Chi N, Epstein JA (2002) Getting your Pax straight: Pax proteins in development and disease. Trends Genet 18:41–47
Frascella E, Toffolatti L, Rosolen A (1998) Normal and rearranged PAX3 expression in human rhabdomyosarcoma. Cancer Genet Cytogenet 102:104–109
Frigerio G, Burri M, Bopp D, Baumgartner S, Noll M (1986) Structure of the segmentation gene paired and the Drosophila PRD gene set as part of a gene network. Cell 47:735–746
Frost V, Grocott T, Eccles MR, Chantry A (2008) Self-regulated Pax gene expression and modulation by the TGFbeta superfamily. Crit Rev Biochem Mol Biol 43:371–391
Fukuda ME, Iwadate Y, Machida T, Hiwasa T, Nimura Y, Nagai Y, Takiguchi M, Tanzawa H, Yamaura A, Seki N (2005) Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 65:5190–5194
Godbout R, Bisgrove DA, Shkolny D, Day RS 3rd (1998) Correlation of B-FABP and GFAP expression in malignant glioma. Oncogene 16:1955–1962
Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR Jr, Gillespie GY (2008) CD133 is a marker of bioenergetic stress in human glioma. PLoS One 3:e3655
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30
Jiang L, Mao P, Song L, Wu J, Huang J, Lin C, Yuan J, Qu L, Cheng SY, Li J (2010) miR-182 as a prognostic marker for glioma progression and patient survival. Am J Pathol 177:29–38
Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215–25, discussion 226–9
Kozmik Z (2008) The role of Pax genes in eye evolution. Brain Res Bull 75:335–339
Lang D, Lu MM, Huang L, Engleka KA, Zhang M, Chu EY, Lipner S, Skoultchi A, Millar SE, Epstein JA (2005) Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433:884–887
Lang D, Powell SK, Plummer RS, Young KP, Ruggeri BA (2007) PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol 73:1–14
Liu Y, Zhu H, Liu M, Du J, Qian Y, Wang Y, Ding F, Gu X (2011) Downregulation of Pax3 expression correlates with acquired GFAP expression during NSC differentiation towards astrocytes. FEBS Lett 585:1014–1020
Mansouri A, Hallonet M, Gruss P (1996) Pax genes and their roles in cell differentiation and development. Curr Opin Cell Biol 8:851–857
Medic S, Ziman M (2009) PAX3 across the spectrum: from melanoblast to melanoma. Crit Rev Biochem Mol Biol 44:85–97
Muratovska A, Zhou C, He S, Goodyer P, Eccles MR (2003) Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22:7989–7997
Noll M (1993) Evolution and role of Pax genes. Curr Opin Genet Dev 3:595–605
Parker CJ, Shawcross SG, Li H, Wang QY, Herrington CS, Kumar S, MacKie RM, Prime W, Rennie IG, Sisley K, Kumar P (2004) Expression of PAX 3 alternatively spliced transcripts and identification of two new isoforms in human tumors of neural crest origin. Int J Cancer 108:314–320
Plummer RS, Shea CR, Nelson M, Powell SK, Freeman DM, Dan CP, Lang D (2008) PAX3 expression in primary melanomas and nevi. Mod Pathol 21:525–530
Rajan P, Panchision DM, Newell LF, McKay RD (2003) BMPs signal alternately through a SMAD or FRAP-STAT pathway to regulate fate choice in CNS stem cells. J Cell Biol 161:911–921
Robson EJ, He SJ, Eccles MR (2006) A PANorama of PAX genes in cancer and development. Nat Rev Cancer 6:52–62
Scholl FA, Kamarashev J, Murmann OV, Geertsen R, Dummer R, Schafer BW (2001) PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res 61:823–826
Schulte TW, Toretsky JA, Ress E, Helman L, Neckers LM (1997) Expression of PAX3 in Ewing’s sarcoma family of tumors. Biochem Mol Med 60:121–126
Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR (1998) Brain tumor survival: results from the National Cancer Data Base. J Neurooncol 40:151–160
Wu M, Li J, Engleka KA, Zhou B, Lu MM, Plotkin JB, Epstein JA (2008) Persistent expression of Pax3 in the neural crest causes cleft palate and defective osteogenesis in mice. J Clin Invest 118:2076–2087
Acknowledgments
This work was supported by the Nature Science Foundation of China Ministry of Health (2010-2-025), Natural Science Program of Jiangsu Department of Finance (2010-WS-03), Natural Science Program of Nantong University (10Z062), and the Nature Scientific Innovation Foundation of Nantong University (YKC11012).
Author information
Authors and Affiliations
Corresponding author
Additional information
Jian Chen and Liang **a contributed equally to this work.
Rights and permissions
About this article
Cite this article
Chen, J., **a, L., Wu, X. et al. Clinical Significance and Prognostic Value of PAX3 Expression in Human Glioma. J Mol Neurosci 47, 52–58 (2012). https://doi.org/10.1007/s12031-011-9677-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-011-9677-1